In fiscal 2025, which ended Dec 28, 2025, Quidelortho Corp reported revenue of $2.7 billion, down 1.9% from the year before. It recorded a net loss of $1.1 billion. The operating loss came to $919.2 million, an operating margin of -33.7%. Diluted earnings per share were -$16.69. Over the twelve months ended Sep 27, 2026, revenue was $2.6 billion and the net loss was $369.2 million. Across the 4 fiscal years shown, revenue shrank from $3.3 billion in fiscal 2022 to $2.7 billion in fiscal 2025, about 5.8% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 27, 2026
|
FY 2025
Dec 28, 2025
|
FY 2024
Dec 29, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Jan 1, 2023
|
|---|---|---|---|---|---|
| Revenue |
2,593
-4.5%
|
2,730
-1.9%
|
2,783
-7.2%
|
2,998
-8.2%
|
3,266
|
| Research and development |
182
-3.1%
|
186
-14.9%
|
219
-10.7%
|
245
+30.4%
|
188
|
| Selling, general and administrative |
766
+3.6%
|
746
-2.7%
|
767
+0.5%
|
763
+22.9%
|
621
|
| Operating income |
-127
+86.6%
|
-919
+53.1%
|
-1,961
-1509.7%
|
139
-83.5%
|
844
|
| Pretax income |
-336
+70.4%
|
-1,108
+48.0%
|
-2,132
-7224.7%
|
-29
-104.0%
|
736
|
| Income tax |
33
-23.3%
|
24
+130.3%
|
-80
-318.4%
|
-19
-110.1%
|
187
|
| Net income |
-369
+68.7%
|
-1,132
+44.8%
|
-2,052
-20216.8%
|
-10
-101.8%
|
549
|
| Basic EPS |
-5.40
+69.0%
|
-16.69
+45.4%
|
-30.54
-20260.0%
|
-0.15
-101.6%
|
9.66
|
| Diluted EPS |
-5.40
+69.0%
|
-16.69
+45.4%
|
-30.54
-20260.0%
|
-0.15
-101.6%
|
9.56
|
| Weighted average shares, basic |
68
+1.0%
|
68
+0.9%
|
67
+0.6%
|
67
+17.6%
|
57
|
| Weighted average shares, diluted |
68
+1.0%
|
68
+0.9%
|
67
+0.6%
|
67
+16.4%
|
57
|
| Other measures | |||||
| Depreciation and amortization |
462
+5.2%
|
442
-2.5%
|
453
-0.8%
|
457
+61.2%
|
284
|
| EBITDA |
334
+165.0%
|
-477
+68.3%
|
-1,508
-352.8%
|
596
-47.1%
|
1,127
|
| Interest coverage |
-0.60x
|
-5.18x
|
-11.99x
|
—
|
—
|
| Margins | |||||
| Operating margin |
-4.91%
|
-33.67%
|
-70.46%
|
4.64%
|
25.83%
|
| Pretax margin |
-12.96%
|
-40.57%
|
-76.59%
|
-0.97%
|
22.53%
|
| Profit margin |
-14.24%
|
-41.45%
|
-73.74%
|
-0.34%
|
16.80%
|
| EBITDA margin |
12.89%
|
-17.48%
|
-54.17%
|
19.89%
|
34.52%
|
| Effective tax rate |
—
|
—
|
—
|
—
|
25.44%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.